dc.contributor.author | Kumaraguru, J | |
dc.contributor.author | Flanagan, SE | |
dc.contributor.author | Greeley, SA | |
dc.contributor.author | Nuboer, R | |
dc.contributor.author | Støy, J | |
dc.contributor.author | Philipson, LH | |
dc.contributor.author | Hattersley, AT | |
dc.contributor.author | Rubio-Cabezas, O | |
dc.date.accessioned | 2016-03-03T15:35:41Z | |
dc.date.issued | 2009-05-12 | |
dc.description.abstract | OBJECTIVE To assess if tooth discoloration is a novel side effect of sulfonylurea therapy in patients with permanent neonatal diabetes due to mutations in KCNJ11. RESEARCH DESIGN AND METHODS A total of 67 patients with a known KCNJ11 mutation who had been successfully transferred from insulin injections onto oral sulfonylureas were contacted and asked about the development of tooth discoloration after transfer. RESULTS Altered tooth appearance was identified in 5 of the 67 patients. This was variable in severity, ranging from mild discoloration/staining (n = 4) to loss of enamel (n = 1) and was only seen in patients taking glibenclamide (glyburide). CONCLUSIONS These previously unreported side effects may relate to the developing tooth and/or to the high local concentrations in the children who frequently chewed glibenclamide tablets or took it as a concentrated solution. Given the multiple benefits of sulfonylurea treatment for patients with activating KCNJ11 mutations, this association warrants further investigation but should not preclude such treatment. | en_GB |
dc.description.sponsorship | This work was funded by the Welcome Trust (grant 067463/Z/2/Z), National Institutes of Health Grants DK-44752 and DK-20595, and a gift from the Kovler Family Foundation. S.E.F. is the Sir
Graham Wilkins, Peninsula Medical School Research Fellow. A.T.H. is a Welcome Trust
Research Leave Fellow. O.R.-C. was supported by an “Ayuda para contratos post-Formacio´n
Sanitaria Especializada” from the “Instituto de Salud Carlos III” (FIS CM06/00013) | en_GB |
dc.identifier.citation | Vol. 32, no. 8, pp. 1428-1430 | en_GB |
dc.identifier.doi | 10.2337/dc09-0280 | |
dc.identifier.other | dc09-0280 | |
dc.identifier.uri | http://hdl.handle.net/10871/20439 | |
dc.language.iso | en | en_GB |
dc.publisher | American Diabetes Association | en_GB |
dc.relation.url | http://www.ncbi.nlm.nih.gov/pubmed/19435956 | en_GB |
dc.relation.url | http://care.diabetesjournals.org/content/32/8/1428 | en_GB |
dc.rights | © 2009 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. | en_GB |
dc.subject | Dental Enamel Hypoplasia | en_GB |
dc.subject | Diabetes Mellitus | en_GB |
dc.subject | Glyburide | en_GB |
dc.subject | Humans | en_GB |
dc.subject | Infant, Newborn | en_GB |
dc.subject | Insulin | en_GB |
dc.subject | Mutation | en_GB |
dc.subject | Potassium Channels, Inwardly Rectifying | en_GB |
dc.subject | Tooth Discoloration | en_GB |
dc.title | Tooth discoloration in patients with neonatal diabetes after transfer onto glibenclamide: a previously unreported side effect. | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2016-03-03T15:35:41Z | |
dc.identifier.issn | 0149-5992 | |
exeter.place-of-publication | United States | |
dc.description | Published | en_GB |
dc.description | Journal Article | en_GB |
dc.description | Multicenter Study | en_GB |
dc.description | Research Support, N.I.H., Extramural | en_GB |
dc.description | Research Support, Non-U.S. Gov't | en_GB |
dc.identifier.eissn | 1935-5548 | |
dc.identifier.journal | Diabetes Care | en_GB |